Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Antimicrobial Resistance (AMR) occurs when pathogens change and find ways to resist the effects of antimicrobial agents. The pathogens survive, grow and spread their resistance. This process of adaptation leads to AMR.1
Antimicrobial resistance, particualrly in Gram-negative bacteria, is widely recognised as one of the biggest threats to global health today, with the potential to affect anyone, of any age, in any country.2,3,4
Globally, AMR causes 700,000 deaths annually. Without actions by governments, industry and society, AMR is expected to casue 10 million deaths by 2050 - more than currently die from cancer.1
Pfizer has one of the industry’s largest and most diverse portfolios of antimicrobials and is proud to be taking a lead in the fight to tackle AMR.5 We are deeply committed to working closely with the infectious disease community to address AMR6 through5:
|
Active stewardship: to ensure patients receive the correct antibiotic, according to independent guidelines, only if needed and for the right duration7
|
|
Innovative surveillance tools: to help physicians better understand current resistance patterns |
|
Global policy leadership: to facilitate antibiotic development and proper use |
|
Diverse portfolio: medicines and vaccines to treat and help prevent serious infections around the world |
|
Manufacturing: responsible practices that do not harm human health or the environment |
Pfizer have pledged US $100 million to the Antimicrobial Resistance (AMR) Action Fund which launched in July 2020, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic resistant infections.
The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies, philanthropies, development banks and multilateral organisations to re-invigorate and accelerate antiobiotic development.8
Prescribing Information
Zavicefta® (avibactam sodium, ceftazidime pentahydrate)
Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for solution for infusion
Cresemba® (isavuconazole)
Great Britain
Cresemba® (isavuconazole) 100mg hard capsules
Cresemba® (isavuconazole) 200mg powder for concentrate for solution for infusion
Northern Ireland
Cresemba® (isavuconazonium sulfate) 200mg powder for concentrate for solution for infusion and Cresemba 100mg hard capsules
Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo® (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo® (ceftaroline fosamil) 600mg powder for concentrate for solution for infusion
We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?